Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare sector during the peak of the COVID-19 crisis, the pharmaceutical giant is currently navigating one of the most challenging chapters in its [...]
As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global pandemic, the company is now deep into its "Act 2"—a pivot from a single-product powerhouse to a diversified platform focused on oncology, latent viruses, [...]
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 7.8% in the afternoon session after the stock's positive momentum continued as the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would invest up to $54.3 million to support a pivotal Phase 3 clinical trial for the company's investigational mRNA-based pandemic influenza vaccine candidate, mRNA-1018.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 4% in the morning session after the company announced it would receive up to $54.3 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance a late-stage trial for its experimental bird flu vaccine.
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p.m. ET / 4:30 p.m. PT.
New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall Street's expectations. The announcement immediately sent shockwaves through the market, with Pfizer's stock experiencing a notable decline as investors
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)
Rapid spending isn’t always a sign of progress.
Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings.
New York, NY – December 9, 2025 – Growth stocks within the S&P 500 have continued their remarkable ascent, significantly outpacing their value counterparts throughout 2025. This enduring trend, largely fueled by the relentless innovation and investor enthusiasm surrounding artificial intelligence (AI) and the performance of mega-cap technology firms, has extended
In the intricate dance of global finance, where algorithms whir and economic data points are meticulously dissected, an often-overlooked yet profoundly powerful force consistently asserts its influence: market sentiment and investor psychology. As 2025 unfolds, these emotional and cognitive currents are not merely ripples but rather a surging tide, dictating
